Phase i evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer

Gastrointestinal Endoscopy

Volumn 75, Issue 6, 2012, Pages

  Chang, Kenneth J ^a   Reid, Tony ^b,c   Senzer, Neil ^d   Swisher, Stephen ^e   Pinto, Harlan ^b   Hanna, Nader ^f   Chak, Amitabh ^g   Soetikno, Roy ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d Mary Crowley Medical Research Center   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

5 fluorouracil; 5 FU; DFS; disease free survival; DLT; dose limiting toxicity; OS; overall survival; particle units; pathologic complete response; pCR; PU; radiation therapy; RT; TE; thrombotic thromboembolic event; TNF ; tumor necrosis factor

Indexed keywords

CISPLATIN; FLUOROURACIL; GOLNERMINOGENE PRADENOVEC;

ADVANCED CANCER; ARTICLE; AUTOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG SAFETY; DRUG TOLERANCE; ENDOSCOPY; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FATIGUE; FEMALE; FEVER; GENE; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR ALPHA GENE; VOMITING;

EID: 84861530230     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2012.01.042     Document Type: Article

References (13)

1. T. Kim, S.R. Grobmyer, R. Smith Esophageal cancer-the five year survivors J Surg Oncol 103 2011 179 183
2. L.J. Old Tumor necrosis factor (TNF) Science 230 1985 630 632
3. N. Yamauchi, H. Kuriyama, N. Watanabe Intracellular hydroxyl radical production induced by recombinant human tumor necrosis factor and its implication in the killing of tumor cells in vitro Cancer Res 49 1989 1671 1675
4. J.W. Larrick, S.C. Wright Cytotoxic mechanism of tumor necrosis factor-alpha FASEB J 4 1990 3215 3223
5. D.E. Hallahan, H.J. Mauceri, L.P. Seung Spatial and temporal control of gene therapy using ionizing radiation Nat Med 1 1995 786 791
6. V.K. Gupta, J.O. Park, N.T. Jaskowiak Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma Ann Surg Oncol 9 2002 500 504
7. R.J. Korst, M. Ailawadi, J.M. Lee Adenovirus gene transfer vectors inhibit growth of lymphatic tumor metastases independent of a therapeutic transgene Hum Gene Ther 12 2001 1639 1649
8. D. Labow, S. Lee, R.J. Ginsberg Adenovirus vector-mediated gene transfer to regional lymph nodes Hum Gene Ther 11 2000 759 769
9. D.R. Spigel, F.A. Greco, A.A. Meluch Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction J Clin Oncol 28 2010 2213 2219
10. S.E. Greer, P.P. Goodney, J.E. Sutton Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis Surgery 137 2005 172 177
11. N. Starling, S. Rao, D. Cunningham Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group J Clin Oncol 27 2009 3786 3793
12. A. Varki Trousseau's syndrome: multiple definitions and multiple mechanisms Blood 110 2007 1723 1729
13. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration application to healthy patients undergoing elective procedures: a report by the American Society of Anesthesiologist Task Force on Preoperative Fasting Anesthesiology 90 1999 896 905